Tagged with GEN

Lithuania Janis Kalejs, country manager Baltics at Mylan, discloses the strategies he has used to successfully lead his affiliate through corporate changes and explains how Mylan aims to continue providing affordable as well as high-quality treatments to patients in the region. What is the history of Mylan in the Baltics? “The…

Serbia Ana Popovic, general manager of Serbia’s generics association, Genezis, gives her thoughts on how the generics industry has progressed in the country, what room for improvement remains, and the impact of EU succession. Where does Genezis stand in 2017 and what is keeping you busy at the moment? “The Serbian…

Canada The government of the French-speaking Canadian province of Québec stands out for undertaking healthcare reforms while appreciating the need to join hands with industry when it comes to the promotion of health innovation. “Quebec has the most aggressive approach of any province in this country [for generics pricing]” Dr. Gaétan…

Poland Agnieszka Grzybowska-Zalewska, general manager of Sanofi Genzyme Poland, reflects on the company’s stable growth over the last few years and the market access challenges they have encountered along the way. Moreover, she highlights the importance of achieving reimbursement for three key products for Multiple Sclerosis and Oncology as well as…

Serbia Milos Davidovic, Mylan’s country manager responsible for Serbia, Slovenia, Macedonia, and Montenegro, reveals the made-to-measure market approach that he has been implementing in the region for the past six years while highlighting the crucial role of employing a highly educated, expert workforce. What potential did Mylan see in Serbia, and…

Poland Dr. Wolfgang Wagner, regional director of Wörwag EU and CEE, highlights the ongoing process of the company to integrate itself within each respective healthcare community so patients can receive better market access to their biofactor therapies. Furthermore, he discusses the need to highlight the pharmacoeconomic impact of their products to…

India A strong advocate for quality, Dilip Surana, chairman and managing director of Micro Labs, explains how the company’s strong focus on the quality of its products and move to specialty generics has led them to success in both the Indian and US markets. When we met in 2011, the company…

Canada Dr. David Goodman, CEO of Pharmascience, talks about the strategy for the international expansion of the company, key for which are long-lasting partnerships. He also analyzes the re-organization of the company amongst the two main axes of generics and branded products and highlights its dedication to R&D, especially in the…

India Amit Mookim, IQVIA’s general manager for South Asia, discusses the major trends impacting the Indian pharmaceutical market and how Indian companies are rethinking their commercial strategies and becoming more specialized to reach sophisticated international markets. Mr. Mookim, could you give our international readers a brief introduction of IQVIA and explain…

Poland Stefan Buguslawski, president of PEX Pharmasequence, a leading Polish healthcare consultancy and market research company, highlights the current obstacles facing the Polish healthcare market and the dynamics of the domestic pharmaceutical industry. He also discusses the innovative services they provide and how their offering will develop in the future. As…

Switzerland Dr. Raymond De Vré, senior VP and head of Business Operations and Strategy, Biologics at Dr. Reddy’s in Switzerland, discusses scaling up the Indian-headquartered company’s biosimilars business globally and the importance of selecting Switzerland as the location for regional headquarters.   The main challenge in the mature markets is the…

Poland Wojciech Sulimierski, general manager of Aspen Poland and CEE, discusses the opening of the regional operations in 2014 and the importance of the CEE region as the company establishes itself in the global pharmaceutical ecosystem. Moreover, he highlights the impact of global acquisitions and the niche area model they have…